GNU101 / Gnubiotics - LARVOL DELTA

Glycan-programmed T cell immunity: Effective adoptive T cell transfer in a CRC preclinical model (ESMO 2024) - "Potent, specific anti-tumor T cell response with long-lasting effects elicited by GNU101 uncover a new field in tumor biology. By provoking a distinct, tumor-specific response this formulation has clear benefits over approaches that result in the non-specific killing of fast proliferating cells (e.g. cytostatic drugs) or general immune activation (i.e."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

A multi-targeted T-cell engagement of PD1-resistant colorectal cancer cells via delivery of glycopeptide conjugates. (ASCO 2023) - "We demonstrate the immunomodulatory and therapeutic potential of GNU-101 in a pre-clinical mouse study in which the growth of established tumors was significantly reduced, either as a standalone therapy or in combination with existing treatment. By specifically promoting anti-cancer CD8+ T cells while reducing immunosuppressive signals, this easy-to-administer glycopeptide has the potential to create the conditions for long-term cancer control and improve treatment outcomes in cancer that are frequently resistant to immunotherapy, such as many epithelial cancers."

Colorectal Cancer • Gastrointestinal Cancer • Immune Modulation • Oncology • Solid Tumor • CD4 • CD8 • FOXP3 • GZMB • HAVCR2 • IFNG • PD-1

Gnubiotics Sciences Announces Funding from the Swiss Innovation Agency to Accelerate Development of Glycopeptide Mediated Immunotherapies against Solid Tumors (Businesswire) - "Gnubiotics Sciences...announced that the Swiss Innovation Agency (Innosuisse) will support a research collaboration with the University Hospital Zürich to accelerate the development of Gnubiotics’ GLAAD technology in a range of solid tumors. The total project cost of CHF 1.4 million (USD 1.4 million) will be supported by the grant from Innosuisse as well as contributions from Gnubiotics....The sponsored project will advance GNU201 and GNU101, as potential first-in-class immunotherapeutics that steer immune responses to control growth in solid tumors expressing altered O-glycan profiles thus responding to a critical need in non-responding patients. The multi-year project which will include dose-finding and key translational studies, forms a core part of a broader preclinical development plan that will support an Investigational New Drug Application (IND)."

Financing • Licensing / partnership • Oncology • Solid Tumor